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Abstract
Background: DNA methylation is a major epigenetic modification important for regulating gene
expression and suppressing spurious transcription. Most methods to scan the genome in different
tissues for differentially methylated sites have focused on the methylation of CpGs in CpG islands,
which are concentrations of CpGs often associated with gene promoters.
Results:  Here, we use a methylation profiling strategy that is predominantly responsive to
methylation differences outside of CpG islands. The method compares the yield from two samples
of size-selected fragments generated by a methylation-sensitive restriction enzyme. We then
profile nine different normal tissues from two human donors relative to spleen using a custom array
of genomic clones covering the euchromatic portion of human chromosome 1 and representing
8% of the human genome. We observe gross regional differences in methylation states across
chromosome 1 between tissues from the same individual, with the most striking differences
detected in the comparison of cerebellum and spleen. Profiles of the same tissue from different
donors are strikingly similar, as are the profiles of different lobes of the brain. Comparing our
results with published gene expression levels, we find that clones exhibiting extreme ratios
reflecting low relative methylation are statistically enriched for genes with high expression ratios,
and vice versa, in most pairs of tissues examined.
Conclusion: The varied patterns of methylation differences detected between tissues by our
methylation profiling method reinforce the potential functional significance of regional differences
in methylation levels outside of CpG islands.
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Background
DNA methylation is a major epigenetic modification that
is vital to mammalian development [1]. Methylation is
carried out by DNA methyltransferases [2] and can sup-
press the initiation of transcription of a locus [3]. Methyl-
ation plays a significant role in genomic imprinting, X-
inactivation, and silencing of parasitic sequences [4-7].
Acquired DNA methylation differences might account for
some phenotypic differences between monozygotic twins
[8]. Aberrant methylation can cause various syndromes
[9-14] and contribute to tumorigenesis by decreasing
activity of tumor suppressor genes [15], activating proto-
oncogenes [16], or overall methylation imbalance [17]
(reviewed in [18]).
In mammals, methylation occurs preferentially at
cytosines that are followed by guanine (CpG). CpG dinu-
cleotides are relatively infrequent in the human genome,
except in CpG islands, which are small (0.2 to 2 kb)
regions highly enriched in CpGs. Approximately 50 to
60% of gene promoters lie in CpG islands [19-21]. Meth-
ylation can inhibit binding of transcription factors to
these sequences directly by altering the structure of the
recognition site, or indirectly by recruiting repressive pro-
teins with methyl-binding domains [22-25].
However, methylation of CpG island promoters does not
always correlate with gene expression levels. Most inactive
promoters are not methylated [3,26]. The CpG islands of
some tissue-specific genes remain unmethylated in tissues
where the gene is not expressed (such as MyoD in non-
muscle tissues) [27-29]. Intriguingly, while promoters are
less methylated on the active X than on the inactive X, the
opposite is true for CpGs in the bodies of genes on the X
chromosome [30]. Highly expressed autosomal genes
were also found to have hypomethylated promoters and
hypermethylated gene bodies in a recent genome-wide
analysis [31]. Moreover, clusters of hypomethylated
regions not limited to CpG islands or promoters have
been found interspersed in stretches of methylated CpGs
[32]. CpG methylation outside of CpG islands is thought
to suppress transcription of transposable elements and
other parasitic sequences [26,33] and/or to suppress spu-
rious initiation of transcription elsewhere, including
within infrequently transcribed genes [34,35]. Clearly
more information on the state of methylation in and out-
side of CpG islands and across different tissues is needed
to clarify the role methylation plays in transcriptional reg-
ulation.
Several approaches have been developed recently to scan
genomes for sites of DNA methylation that might be
important for tissue-specific gene regulation. These
approaches include large-scale sampling of DNA
sequences after bisulfite conversion of unmethylated
cytosines to uracil [31,33,36-38], a variety of techniques
measuring the differential sensitivity of methylated and
unmethylated sequences to certain restriction enzymes
(for example, RLGS, RDA, HELP, MCAM, and MSCC)
[31,32,39-48], and quantitative analyses of promoter
sequences immunoprecipitated with antibodies that
enrich for methylated cytosines [26,49,50] (reviewed in
[51]). Differences in methylation have been detected
among somatic tissues at up to 15% of the loci analyzed
in these studies [26,31,33,36,45,48,52].
Here, we employ a methylation profiling technique and a
tiling microarray for human chromosome 1 to detect
regional differences in the methylation state between tis-
sues from the same individual. Our approach relies on a
methylation-sensitive restriction enzyme to generate dif-
ferently sized fragments from methylated versus  non-
methylated genomic DNA. Sample differences in frag-
ment yield within a specified size range (80 to 2,500 bp)
are detected by competitive hybridization of size-selected
fragments to a tiling array of genomic clones. This
approach has been used successfully to characterize meth-
ylation patterns in Arabidopsis  methylation mutants
[53,54]. We have combined this technique with a custom
chromosome 1 microarray with a resolution of approxi-
mately 100 kb [55].
Below, we first describe simulation experiments that show
that log ratios measured by the array are a complex func-
tion of the methylation level of the hybridizing DNA and
the GC-content of the array clones. We also predict from
simulations that the array will be more responsive to
methylation changes at dispersed CpG sites than to
changes in CpG islands. We then use the array to profile
chromosome 1 methylation in several tissues from two
human donors, demonstrating that the technique yields
highly reproducible results. The methylation profiles we
obtain vary between different human tissues, but profiles
of the same tissue from two different individuals are sim-
ilar. We then describe our use of bisulfite sequencing to
confirm an array finding of hypomethylation in heart
DNA around the RYR2 gene and to confirm predictions
from our simulations that observed log ratios are
impacted by methylation differences outside of CpG
islands. We analyze published data on the relative expres-
sion levels of genes and detect significantly different
expression ratios for genes residing in regions exhibiting
extremely high versus low methylation ratios in all six of
the tissue comparisons analyzed.
Results
Simulations predict impact of GC content and CpG 
distribution on fragment yield
In our methylation-profiling technique (Figure 1), DNAs
obtained from test and reference samples are digested
with a methylation-sensitive restriction enzyme, HpaII,
which cleaves CCGG sites that are not modified by meth-Epigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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ylation. Therefore, the methylation status for each sample
influences the size distribution of restriction fragments:
unmethylated DNA is cut into smaller pieces than is
highly methylated DNA. After digestion, fragments longer
than approximately 80 bp and shorter than approximately
2.5 kb are isolated by sucrose-gradient fractionation, and
test and reference DNAs are differentially labeled with
fluorochromes by random priming. Thus, size fractiona-
tion is the primary determinant for distinguishing
between two differentially methylated samples.
These samples are allowed to competitively hybridize to
2,136 genomic clones (bacterial artificial chromosomes
(BACs), P1-derived artificial chromosomes (PACs), fos-
mids, cosmids) on a microarray in the presence of Cot1
DNA to suppress repetitive sequences. The array contains
2,049 clones that cover most of the euchromatic portions
of human chromosome 1, 17 clones that are distributed
sparsely on chromosome X, and 70 other clones. Average
log2 ratios of test-to-reference fluorescence intensities are
generated from the duplicate spots for each clone whose
measurements pass quality control tests (see Methods).
Since the median size of the genomic inserts of the clones
on the array is 159 kb, the signal ratio for a given clone is
a complex function of the methylation states of HpaII sites
in the sample and reference (which might both be hetero-
geneous mixtures of cells with different methylation pat-
terns) and the cumulative length (minus repeats) of the
resulting HpaII fragments within the size range of approx-
Schematic of methylation profiling technique Figure 1
Schematic of methylation profiling technique. DNA is harvested from samples (1) and digested with methylation-sensi-
tive enzyme, HpaII, which cuts at its CCGG target site only if the CpG is not methylated (2). The DNA is then size-fraction-
ated on a sucrose gradient, followed by determination of fragment size by agarose gel electrophoresis in order to choose 
fractions containing fragments > approximately 80 bp and < approximately 2.5 kb; in this example, fractions represented by 
lanes numbered 3 to 10 (3). Test and reference samples are then differentially labeled (4) and competitively hybridized to a 
clone-based microarray containing 2,049 clones for chromosome 1, 17 clones for the X chromosome, and 70 other clones (5). 
The signal intensities of each fluorescence channel are expressed as a ratio, log2 transformed, and then loess normalized on the 
percent GC content of clone sequences (6).
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imately 80 to 2,500 bp in the genomic interval covered by
the clone.
We used simulations to understand how methylation dif-
ferences between samples might influence the relative flu-
orescence ratios measured for large-insert clones on the
array. In order for the amount of hybridizing material gen-
erated from two samples to differ, the methylation state of
the sample must yield, after HpaII digestion, a signifi-
cantly higher or lower amount of material in fragments
within the size range 80 to 2,500 bp from the test sample
compared with the reference. Methylation can impact the
amount of product in two opposing ways (Figure 2A). For
example, consider two neighboring HpaII fragments, each
around 2 kb in size. If the HpaII site between them is
methylated, then the fragments remain joined and exceed
the upper size cut-off (2.5 kb). Here, methylation reduces
fragment yield through the size filter (fragments adjoining
sites marked "a" in Figure 2A). Conversely, methylation
could increase fragment yield through the size filter for
other regions, such as CpG islands, which have a high
density of HpaII sites (fragments adjoining sites marked
"c" in Figure 2A). HpaII fragments derived from unmeth-
ylated CpG islands could be excluded due to their small
size (<80 bp), whereas HpaII's inability to cut the same
regions when methylated could generate fragments that
pass the size filter. In yet other cases, methylation might
have no effect on the amount of size-selected hybridizing
material (sites marked "b" in Figure 2A).
In order to simulate the relative fragment yield for an
entire BAC at different methylation levels, we wrote a
PERL script to randomly assign each HpaII site in a BAC's
sequence to be methylated or unmethylated, so as to
achieve various user-specified average overall levels of
methylation. The script performed in silico HpaII digestion
of the resulting partially methylated sequence and the
size-fractionation step. It also masked the sequences using
RepeatMasker [56], which mimics the Cot1 repeat-sup-
pression step necessary to achieve specificity in array
hybridization. The output is total unmasked base pairs in
fragments passing the size filter, which simulates labeling
by random priming [57].
Our simulations show that yield of total unmasked base
pairs passing the size filter from the region corresponding
to any given clone on the array decreases approximately
linearly with increasing average per cent methylation. Fig-
ure 2B shows the results across a range of methylation lev-
els for BAC RP11-47A4 (AL391809), an outlying clone in
the heart-versus-spleen comparisons and the object of
experimental validation below. This negative slope indi-
cates that the array response is dominated by methylation
status at HpaII sites between larger fragments where
increased methylation would reduce yield through the
size filter (sites of type a in Figure 2A), and that smaller
HpaII fragments like those in CpG islands (sites of type c
in Figure 2A) have a negligible effect on the yield of size-
selected fragments corresponding to any array clone. Sim-
ulations for all clones on the array show a similar negative
correlation between fragment yield through the size filter
and methylation level. Figure 2C and 2D display results
for two selected methylation levels, demonstrating that a
sample uniformly methylated at 40% of sites (Figure 2C,
black contours) yields more hybridizing material for all
array BACs than a sample with 80% methylation (Figure
2C, gray contours) and positive predicted log ratios for all
array BACs (Figure 2D). A caveat of our simulations is that
we assumed that all CpG dinucleotides had an equal
chance of being methylated. More sophisticated simula-
tions might model local heterogeneity, such as that
observed in our bisulfite sequencing analyses (see
Results), or the differences between CpG islands and
other regions, but would need a good model to describe
how methylation is distributed across sites. Additional
simulations show that the relationship between fragment
yield and methylation level would have a positive slope
only if CpG islands comprise more than 30% of a clone's
sequence (data not shown), and that is not the case for
any clone on the array. Thus, signal intensity differences
between clones or samples are likely to be predominated
by methylation differences at CpGs outside of CpG
islands.
Simulations also demonstrate a strong relationship
between fragment yield and the percentage of bases that
are either G or C (GC%) in the probed sequence. Figure
2A helps explain how GC content can affect measured
log2 ratios. In this schematic example, HpaII sites are rela-
tively frequent in BAC 1, so that many fragments pass the
size filter in both samples 1 and 2. The increased methyl-
ation of sample 2 causes a relatively modest reduction in
hybridizing material for BAC 1. In contrast, BAC 2 has
lower GC content and thus larger HpaII fragments, on
average, and therefore the same increased methylation
level in sample 2 has a much more dramatic effect,
entirely preventing any material passing the 80 to 2,500
bp size filter. This more dramatic effect would result in a
more extreme measured log ratio for BAC 2 than BAC 1
despite the fact that both BACs measure the same pair of
samples with the same ratio of methylation levels. Figure
2C shows the positive relationship between total base
pairs in HpaII fragments predicted to pass our size filter
and GC% for the regions represented by the clones on our
array. This positive relationship is seen at all simulated
methylation levels (40% and 80% are shown in Figure
2C), except at the extreme of 100% methylation, when the
DNA would not be cut at all. Moreover, the log2 ratio of
yield for two samples simulated to have different overall
methylation levels (test low, reference high) is positive forEpigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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Fragment yield simulations Figure 2
Fragment yield simulations. (A). The same methylation ratio (1:2) can give different measured ratios for BACs of different 
GC content. Horizontal lines represent the genomic region of a BAC in a single hybridizing sample. Sample 2 is twice as meth-
ylated as sample 1. The upper two rows represent a BAC of higher GC content than the lower rows. Vertical ticks represent 
unmethylated (digestable) HpaII sites; check marks denote HpaII fragments passing the size filter. HpaII sites methylated in sam-
ple 2 but not sample 1 are marked with letters (see text). (B) Simulations based on BAC RP11-47A4. The amount of hybridiz-
ing material decreases with increasing methylation. (C) Simulation results for all array BACs. Contour plots summarize the 
amount of hybridizing material for all BACs at 40% methylation (black contours) and 80% (gray). (D) Predicted ratios when 
samples of 40% (test) and 80% (reference) methylation are co-hybridized. (E) A more complex scenario results in an opposite 
relationship between GC content and ratio. In this scenario, each BAC is simulated to report cross-hybridizing material in both 
test and reference channels equal to 5% of the number of bases of repetitive DNA it contains. (F) Real data for a selected array 
(male liver:spleen) show that, as predicted, the amount of hybridizing material is higher for higher GC content BACs (liver 
intensities, black contours; spleen, gray). (G) Measured ratios from the same array (liver:spleen) also have a strong relationship 
with GC content, as predicted if samples have different overall methylation levels. (H) GC-content-normalized ratios for the 
same array.
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all clones on the array, but the ratios are negatively corre-
lated with clone GC content, even though simulated
methylation levels were uniform (Figure 2D). The slope of
this relationship between log2 ratio and GC% is influ-
enced by choice of overall methylation levels simulated
for the two samples, relative simulated levels of back-
ground signals on the array spots (for example, a fixed
amount of non-specific signals or signals due to incom-
pletely suppressed repetitive elements), and allowance for
variation of actual methylation levels with GC%. In fact,
some combinations of these variables can yield a gener-
ally positive (but curved) slope in the relationship
between log2 ratio and GC% (Figure 2E). To demonstrate
this effect, we simulated adding cross-hybridizing signal
proportional to each BAC's repeat content to both test and
reference channels. The predicted ratio for BACs of low
GC content is greatly reduced, because the cross-hybridiz-
ing material (equal for test and reference) outweighs the
small amount of specific hybridizing material. BACs of
higher GC content receive much more specific hybridizing
material, so the cross-hybridizing material has less effect
and the ratios are much closer to those predicted without
cross-hybridization (compare Figures 2D and 2E).
Experimental data confirm a dependency on GC content.
Note that we do not know the overall average levels of
methylation for any of the samples we used, but any over-
all difference in methylation levels between the two sam-
ples being compared would result in a correlation
between GC content and measured log ratio. In the exam-
ple provided in Figure 2F, a comparison of liver and
spleen tissue from the same donor, both test (liver) and
reference (spleen) signal intensities for clones on the array
increase with increasing clone GC content, and the
observed log2 ratios decrease with clone GC content (Fig-
ure 2G). This plot shows raw ratios, but ratios normalized
by intensity, a common normalization method, show a
similar relationship (not shown). Because much of the
variance in log2 ratios across the genome is accounted for
by variation in GC content, we normalized log2 ratios for
each clone based on its GC% using a loess fit of the rela-
tionship between log2 ratio and GC% measured for each
array experiment. All subsequent plots and analyses use
GC-normalized values. Note that this normalization,
while necessary to correct for clone-to-clone differences in
measured ratios due to differences in GC content,
excludes an ability to detect any true variation in methyl-
ation levels that might correlate with GC content. The GC-
normalized log2 ratios allow us to identify potential differ-
ences in relative methylation levels for clones with similar
GC content (Figure 2H).
Tissue differences in methylation
We next used the profiling method to detect methylation
differences between tissues from the same individual. We
evaluated lung, heart, liver, four regions of the brain (cer-
ebellum, medulla oblongata, occipital lobe and pons),
each from two individuals, as well as testis or ovary from
single individuals. Each tissue was directly compared with
spleen from the same individual to control for any inter-
individual variation in genomic content (for example,
segmental copy number variants and/or restriction frag-
ment length polymorphisms). We also conducted con-
ventional array-comparative genomic hybridization
(CGH) analyses on the tissue samples to verify that no sig-
nificant somatic differences in copy number existed
within the same individual for sequences represented by
our clone array (data not shown). The female lung sample
was excluded from further analyses, because it had an
unusually noisy genomic copy-number profile, suggestive
of random genome instability, with relative copy number
correlating strongly with methylation profile ratios (data
not shown).
To test the reproducibility of the method, we performed
each tissue comparison in triplicate using tissues from
each of two donors. The test replicates were taken from
the same tissue DNA preparation and independently
digested, size-selected, labeled, and hybridized to the
array with similarly processed, but differentially labeled,
spleen DNA. Replicate arrays for a given tissue compari-
son also usually employed different, independently proc-
essed replicates of the donor's spleen reference DNA (see
Additional file 1). The log2 ratios for the replicates, both
within and between donors, correlate very well for all tis-
sue comparisons except those involving the male lung
(Figure 3, Additional files 2, 3, 4, 5; summarized in Table
1). The poor correlation of replicate values of the three
male lung-versus-spleen arrays (Pearson R2  of 0.22 to
0.59) is likely because almost all of these values are close
to zero, and variation is therefore predominantly experi-
mental noise. Apart from lung, we find high Pearson cor-
relation coefficients (R2) for within-donor replicates
(median 0.88, range 0.61 to 0.95, n = 42) (Table 1). Thus,
profiles are robustly conserved across technical replicates
of both test and reference DNA. Correlation coefficients
are also high when ratio values for the same tissue from
different donors are compared (median 0.66, range 0.30
to 0.86, n = 54) (Table 1). Figure 3 shows as examples the
high correlation of log2 ratios from the cerebellum-versus-
spleen arrays obtained using tissues from two individuals,
one male and one female (Pearson R2 = 0.92 comparing
replicates from the same donor, and R2 = 0.86 comparing
samples across donors).
Tissues show distinctly different methylation patterns
along chromosome 1 (Figures 4 and 5). In each plot, we
have highlighted clones that deviate from the overall
median by >4.88 median absolute deviation (MAD)
units, with MAD calculated using the data for clones in a
region of 1q that showed the least biological variation
within and across experiments (see Methods). At oneEpigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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extreme, cerebellum shows a large variation in intensity
ratios from region to region when compared with spleen
for both donors. Regions with the greatest dynamic range
in GC-normalized ratios are distributed across the chro-
mosome, but tend to be GC- and gene-rich regions abun-
dant in HpaII sites (Additional file 6). These
characteristics could potentially contribute to a greater
dynamic range of measured ratios than possible in other
regions of chromosome 1. At the other extreme, lung and
spleen are very similar, with the profiles showing only a
few sites of significant difference (Figure 4).
The methylation profiles of the various lobes of the brain
map are highly correlated, with many of the peaks and
valleys in the profile landscapes mapping to the same
chromosomal domains (Figure 5). This similarity is best
appreciated in the XY-plots provided in Additional files 2,
3, 4, their correlation coefficients summarized in Table 1,
and the hierarchical cluster plots in Additional file 5.
These pronounced common differences might be the
cumulative result of many genes in these regions that are
regulated in a tissue-specific manner, in this case brain- or
spleen-specific. The median Pearson correlation coeffi-
cient of ratios measured for the four different brain por-
tions (each compared with spleen) from the same donor
is 0.45 (range 0.27 to 0.93, n = 108). This level of correla-
tion approaches what we observed when comparing the
same tissue taken from different individuals (see above).
In sharp contrast to the similarity of the brain tissue pro-
files, we observe gross differences between the methyla-
tion profiles of other tissues, perhaps reflecting regions
that are differentially regulated between tissues (Figure 4,
Additional file 4). The correlation coefficients are notably
low when ratios measured for different organs (each rela-
tive to spleen) of the same donor are compared (median
R2 = 0.1, range 0 to 0.44 excluding lung and including a
only single brain part (cerebellum) in these comparisons,
n = 108) (Table 1). Thus, methylation profiles of the same
tissue in different individuals correlate more strongly than
do those of different tissues from the same individual.
The heart-versus-spleen methylation profiles identify an
intermediate number of clones that deviate reproducibly
and significantly from the median ratio in independent
comparisons (Figure 4, Additional files 2 and 7). Many of
these clones were not identified as outliers in other tissue
comparisons, suggesting a real difference in the methyla-
tion status between heart and spleen in these genomic
regions. Below, we focus our bisulfite sequencing assays of
methylation state on two of these clones with outlying
values.
Bisulfite confirmation of methylation differences outside 
of CpG islands
We conducted bisulfite sequence analyses to confirm meth-
ylation differences between heart and spleen for sequence
represented by RP11-47A4 (AL391809), which showed
very high heart-versus-spleen log2 ratios in all replicates of
both donors (Additional files 8 and 9). These very high rel-
ative heart:spleen ratios are predicted to reflect significantly
less methylation of CpGs, and thus more frequent cutting
with HpaII, in heart than spleen in this locus compared
with other regions of chromosome 1 after accounting for
Intra- and inter-individual reproducibility of methylation profiling method Figure 3
Intra- and inter-individual reproducibility of methylation profiling method. A very strong correlation is observed 
between cerebellum:spleen log2 ratios measured using samples from the same donor (A, Pearson R2 = 0.92) and from different 
donors (B, Pearson R2 = 0.86). See also Additional files 2, 3, 4 and 5.
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fluctuations in GC content. This clone contains part of a
heart-specific gene, RYR2, making it an interesting candi-
date for confirmation of this prediction by bisulfite
sequencing. These analyses also confirm our simulations,
which predict that the method is most responsive to meth-
ylation differences outside of CpG islands.
RP11-47A4 encompasses the first exon and part of the first
intron of the RYR2 cardiac receptor gene and this gene's
CpG island (Figure 6, Additional file 8); it contains no
other known gene. This clone gave a high ratio only in
arrays for heart versus spleen (>9 MAD units above the
median) and cerebellum versus spleen (4 to 8 MAD units
above median). RYR2 is expressed at high levels only in
the heart and to a much lesser extent in some parts of the
brain, albeit not cerebellum [58]; its disruption causes
heart defects in humans [59-61]. We characterized the
methylation state in heart and spleen of 27 CpGs distrib-
uted across this clone's sequence outside of the CpG
island (Figure 6, top; Additional file 9). Seven of these
CpGs are in HpaII recognition sites. These HpaII sites were
selected for analysis from among the 174 predicted HpaII
sites in AL391809, because a change in their methylation
status would have a large impact on yield in our proce-
dure. The methylation state of these HpaII sites would
determine whether or not a fragment of 500 to 2,000 bp
containing ≥ 50% unique sequence would pass the size
filter (when unmethylated) or be left joined to a large
flanking fragment and not contribute to the hybridization
signal (when methylated). We treated DNA samples with
bisulfite, amplified regions of interest by PCR using prim-
ers designed to complement bisulfite-converted sequence,
and sequenced cloned amplicons from heart and spleen,
respectively. Our analyses of clones of bisulfite-converted
DNA show that, indeed, all but one of these seven dis-
persed HpaII sites in AL391890 are hypomethylated in
heart compared with spleen, with overall average methyl-
ation per site of 38% in heart compared with 71% in
spleen (Figure 6, top; Additional file 9). Similar results
were found for 20 nearby CpGs in the sequenced ampli-
cons that are not part of HpaII sites (Figure 6, top; Addi-
tional file 9)
Although our simulations predict that the differences
between heart and spleen detected by the array are domi-
nated by methylation differences such as those outside of
CpG islands, we nevertheless examined the methylation
state of RYR2's CpG island, which contains regulatory ele-
ments, GC boxes essential for transcription of this gene,
and spans a total of 181 CpGs. We successfully amplified
two portions of the CpG island, containing a total of 53
CpGs. Overall, CpGs in the island were less methylated
than CpGs distributed outside of the island in both heart
and spleen. CpGs in the first 251-bp CpG island amplicon
(P1) just upstream of the GC-boxes are approximately
3.5-fold less often methylated on average in heart than
spleen, but the second 303-bp amplicon (P2) containing
35 CpGs, including five HpaII sites just downstream of the
Table 1: Pearson correlation coefficients, R2.
n median min max n median min max
Same tissue, Same individual Same tissue, Different individual
All, except lung 42 0.88 0.61 0.95 All, except T & O 54 0.66 0.30 0.86
cerebellum 6 0.93 0.86 0.95 cerebellum 9 0.84 0.82 0.86
pons 6 0.92 0.89 0.93 pons 9 0.67 0.64 0.71
medulla 6 0.92 0.90 0.94 medulla 9 0.66 0.62 0.68
occipital 6 0.87 0.61 0.89 occipital 9 0.66 0.52 0.70
liver 6 0.85 0.68 0.88 liver 9 0.54 0.30 0.70
heart 6 0.77 0.74 0.79 heart 9 0.51 0.39 0.56
testis 3 0.84 0.83 0.85
ovary 3 0.90 0.87 0.91 testis vs ovary 9 0.19 0.14 0.26
lung, male 3 0.31 0.22 0.59
Different tissue, Same individual
All*, except lung 108 0.10 0.00 0.44 *only cerebellum represented from brain
heart vs. ovary 9 0.40 0.38 0.44
heart vs. testis 9 0.23 0.20 0.29
heart vs. cerebellum 18 0.10 0.08 0.14
heart vs. liver 18 0.06 0.01 0.19
liver vs. ovary 9 0.02 0.00 0.07
liver vs. testis 9 0.09 0.05 0.13
liver vs. cerebellum 18 0.03 0.00 0.05
cerebellum vs. ovary 9 0.11 0.09 0.14
cerebellum vs. testis 9 0.16 0.13 0.18
All four brain parts 108 0.45 0.27 0.93Epigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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Methylation profiles of multiple tissues show striking differences Figure 4
Methylation profiles of multiple tissues show striking differences. Cerebellum, heart, liver, lung, testis, and ovary are 
each profiled relative to spleen. With the exception of the ovary:spleen comparison, these representative plots were obtained 
using tissues from the same male donor. The log2 ratios for chromosome 1 clones are indicated at their relative genomic posi-
tion, with the large gap representing the centromere and pericentromeric repeats in 1p11–1q21. The horizontal scale for the 
X chromosome is compressed; the 17 chromosome X clones on the array are actually distributed over 110 Mb. Clones high-
lighted in black have log2 ratios that deviate from the overall median, set here to 0, in either direction by >4.88 median absolute 
deviation (MAD) units, where MAD units are calculated using the data for the clones in the region of 1q marked 'MAD' (posi-
tion 184 to 197 Mb), which showed the least biological variation within and across experiments. High log2 ratios are expected 
for regions hypomethylated relative to clones of similar GC content in the test tissue relative to spleen, whereas low log2 
ratios are expected to represent relatively hypermethylated regions. In the heart-versus-spleen profile, bacterial artificial chro-
mosome (BAC) RP11-47A4, containing part of the RYR2 gene, is highlighted in red and BAC RP11-90O23, containing part of 
ATP2B4, is highlighted in blue.
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Methylation profiles of four lobes of the brain are similar Figure 5
Methylation profiles of four lobes of the brain are similar. (A) Methylation profiles of four different brain regions from 
a female donor, each measured using the same individual's spleen as a reference. Clones highlighted in black have log2 ratios 
that deviate in either direction from the median (set at 0) by >4.88 median absolute deviation (MAD) units calculated from the 
region in 1q marked 'MAD'. See Figure 4 for additional details. (B and C) X-Y scatter plots illustrating the positive correlation 
between log2 ratios measured for different brain parts from female donor (each relative to her spleen). (B) Plot displaying a 
comparison of occipital lobe-versus-spleen and cerebellum-versus-spleen ratios from the female donor (F1 replicates in all 
cases); (C)Plot showing a comparison of pons-versus-spleen and cerebellum-versus-spleen ratios; (D)Plot showing a comparison 
of medulla-versus-spleen and cerebellum-versus-spleen ratios. Pearson correlation coefficients (R2) are 0.43, 0.31 and 0.29 for B, 
C and D, respectively, and indicate significant association at the P < 10-15 level.
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GC boxes, was almost entirely unmethylated in both heart
and spleen (Figure 6, bottom; Additional file 9). Only 0%
and 0.5% of assayed CpGs in P2 were methylated in heart
and spleen, respectively. Thus, if these combined results
apply to the entire CpG island, methylation differences
outside of the CpG island must account for most of the
high signal ratio reported by this clone.
We also find no significant methylation differences
between heart and spleen in the CpG island of ATP2B4,
which is partially contained in RP11-90O23, another
clone exhibiting a high log2 ratio in the heart-versus-spleen
array comparisons (Additional file 7). ATP2B4 (PMCA4b)
is involved in calcium homeostasis and has a role in con-
trolling cardiac hypertrophy in response to increased load
on the heart [62]. We compared the methylation status of
27 CpGs representing approximately 80% of the CpG
island of ATP2B4  in heart and spleen using bisulfite
sequence analysis. The 27 CpGs were similarly unmethyl-
ated in heart and spleen (data not shown). We found aver-
age methylation levels per site of only 0.41% and 1.0% in
heart and spleen, respectively. Thus, methylation differ-
ences in the region in and around ATP2B4 must account
for RP11-90O23's observed high log2 ratio in the heart-
versus-spleen comparison, as we find no methylation dif-
ferences in ATP2B4's CpG island.
Regions with outlying methylation ratios contain genes 
with outlying expression ratios
In order to examine the possible biological significance of
the methylation ratios measured by our arrays, we com-
pared relative methylation levels with relative expression
levels of corresponding genes. In all six of the tissue com-
parisons examined, we found that BACs with apparent
Summary of bisulfite sequencing analyses of male heart (H) and spleen (S) DNA in the RYR2 gene sequence represented by  BAC clone RP11-47A4 (AL391809) Figure 6
Summary of bisulfite sequencing analyses of male heart (H) and spleen (S) DNA in the RYR2 gene sequence 
represented by BAC clone RP11-47A4 (AL391809). More striking methylation differences between these tissues are 
observed at dispersed CpGs outside of the CpG island (top) than in the island (bottom). Each CpG analyzed by bisulfite 
sequencing is represented by a fraction in which the denominator is the total number of sequenced clones of PCR products 
amplified from bisulfite-converted DNA, and the numerator is the number of times methylation was detected at that site. Data 
for CpGs contained within HpaII sites (CCGG) are shaded gray. The results for distributed CpG sites not included in CpG 
islands are indicated along the top, with their relative positions in the AL391809 sequence indicated. Vertical bars separate the 
sites on different PCR amplicons. The CpG island is highlighted by the gray vertical bar in the schematic of the AL391809 
sequence and expanded below to indicate the position of exon 1 of RYR2 gene (white) and the GC boxes (dark gray). Two 
PCR products (P1 and P2) containing multiple CpGs within this CpG island were analyzed by bisulfite sequencing, and the 
results are indicated at the bottom of the figure. Boxes contain overall average methylation levels for heart (H) and spleen (S) 
for CpGs sampled outside of the CpG island (top) and for CpGs sampled within the CpG island (bottom).
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high relative levels of methylation (that is, low array
ratios) tended to contain genes that were expressed at
lower relative levels than BACs with lower methylation
levels. This relationship is expected if regional methyla-
tion assayed by our array, like promoter methylation, is
associated with suppression of transcriptional initiation
[3]. In detail, we compared our results (averaged across
arrays representing the same tissue comparison) with
expression data obtained by Ge et al. [58], who hybridized
RNA from each of 36 normal human tissues singly to
Affymetrix oligonucleotide microarrays to determine
expression levels of around 20,000 human genes (see
Methods). For each gene, we calculated a ratio of expres-
sion levels for six of the tissue pairs evaluated in our meth-
ylation studies, with spleen as the reference tissue in each
case (Ge et al. did not generate expression data for mem-
bers of the remaining tissue pairs). We compared the
methylation array ratios of BAC-sized genomic regions
with the expression ratios of genes whose 5' ends mapped
within those genomic regions, recognizing that such an
analysis likely ignores facets of the complex cause-and-
effect relationships between the methylation levels in dif-
ferent parts of a gene (promoter, body of gene, and so on)
with that gene's expression levels.
While the ratios reported by our methylation-sensitive
arrays and expression ratios show little overall correlation
(data not shown), we noticed a relationship in the
extremes of the distributions: BACs reporting lower levels
of methylation in the test sample than in the reference
(that is, those having very high array ratios relative to oth-
ers on chromosome 1 with similar GC content) tended to
contain genes whose probe sets report higher expression
ratios than average, and that BACs having higher implied
relative methylation levels (low methylation array ratios)
tended to contain genes of lower-than-average expression
ratios. In order to display and test the significance of this
observation, we conservatively classified the BACs into
three categories reporting 'High', 'Mid' or 'Low' implied
methylation levels, using the MAD-based thresholds dis-
cussed above, and examined the expression ratios of genes
mapping to each of those three categories of BACs (Figure
7). Statistical tests that account for the complex many-to-
many relationships in these data (see Methods) indicate
that the observed increases in relative expression level
with decreased relative methylation are statistically signif-
icant in most cases (Figure 7). When less conservative cri-
teria are used for categorizing BAC methylation ratios,
statistically significant relationships are seen for all six tis-
sues comparisons (Additional file 10); the more signifi-
cant results are due in part to a greater number of BACs
(and therefore genes) now in the High and Low groups.
Discussion
DNA methylation is widely recognized as an epigenetic
modification that plays a key role in specifying which por-
tions of the genome are utilized at any given time or place
in eukaryotic organisms, from plants to humans. There-
fore, determining where those marks are made in the
genome and how these marks are interpreted by the pro-
teins that transcribe genes, prevent transcription of other
sequences, package chromatin in the nucleus, or perform
other functions on DNA, has become an important goal.
We have generated chromosome-wide methylation pro-
files of different tissues using an approach that relies on
the action of a methylation-sensitive restriction endonu-
clease and measurement of differences in the relative yield
of size-selected fragments between two samples. Hybridi-
zation of these fragments to a tiling array of large-insert
clones reports coarse regional relative differences in meth-
ylation state. Hybridization to high-resolution oligomer
arrays can reveal much finer-scale fluctuations in methyl-
ation levels along the chromosome (our unpublished
data).
We obtained very different methylation profiles from dif-
ferent organs, suggesting the existence of tissue-specific
epigenetic modification patterns across chromosome 1.
These patterns are conserved across individuals, as the val-
ues measured for the same tissue obtained from different
donors were strongly correlated. As one might expect
given the high inter-individual similarity in methylation
profiles for a given tissue, replicate analyses of the same
tissue from the same donor were even more strongly cor-
related, demonstrating that our technique gives highly
reproducible results. We find that methylation profiles of
the same tissue correlate better across individuals than do
profiles of different tissues from the same individual. This
result corroborates findings of other studies that used
alternative techniques to measure relative methylation
levels [31,33,63].
While most organ profiles were dissimilar, there were
notable exceptions. Interestingly, the profiles for the vari-
ous lobes of the brain were strongly correlated, suggesting
that the shared methylation pattern of these tissues was
established in a shared developmental precursor cell type
and/or that the functions of these cells are sufficiently
similar to be reflected in a similar pattern of epigenetic
modifications. We also observe that some sites stand out
as deviating from the median in multiple tissues. For
example, some clones show similar relative log2 values in
brain profiles and either testis or ovary profiles (Addi-
tional file 4). These similarities might represent spleen-
specific methylation changes (spleen was used as a com-
mon reference sample) or changes common to these other
organs. Other deviant sites are not shared by these differ-
ent organs, such that, in fact, testis and ovary profiles are
poorly correlated with each other.
Our simulations indicate that significant deviations of sig-
nal ratios from the median are influenced predominantlyEpigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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Expression levels are higher for genes in less methylated regions Figure 7
Expression levels are higher for genes in less methylated regions. Each pair of plots shows ratio data for a particular 
tissue compared with spleen, on two different y-axis scales to help illustrate expression differences. For each tissue compari-
son, we divided bacterial artificial chromosome (BACs) into three categories of implied relative methylation levels ('High', 'Mid' 
and 'Low') using median absolute deviation-based thresholds recalculated after averaging ratios across three technical repli-
cates and two donors, if available. Note that low measured array ratios in a BAC-sized genomic region likely reflect more 
methylation in the test tissue than in spleen, relative to other regions of chromosome 1 with similar GC content, and are 
therefore labeled as 'High', and vice versa. The boxplots show the distribution of expression ratios reported by Ge et al. [58] 
for genes whose 5' ends are in BACs of each category. On each plot, the symbol within the bracket represents the P value 
obtained in a test of the null hypothesis that there is no difference in expression ratios of genes in BACs with 'Low' implied rel-
ative methylation levels versus BACs with 'High' relative methylation levels (***, 0 <P < 0.001; **, 0.001 <P < 0.01; *, 0.01 <P < 
0.05; ns, P > 0.1, see Methods). The symbol next to the arrow represents the P value obtained in a trend test of whether 
expression ratios are linearly related to methylation category (coding 'High', 'Mid' and 'Low' categories as -1, 0 and 1, respec-
tively).
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by methylation differences in CpG dinucleotides in HpaII
sites outside of CpG islands. Thus, this method comple-
ments approaches that focus on the methylation states of
CpG dinucleotides in CpG islands. Our bisulfite sequenc-
ing results support the predictions of these simulations.
For example, many more of the significant methylation
differences that might explain the high heart:spleen signal
ratio observed for the RYR2 locus, a gene with heart-spe-
cific function, were found outside of CpG islands than in
them. An important conclusion from these results is that
CpG islands and flanking DNA can have different methyl-
ation patterns, and that tissue-specific genes can be differ-
entially methylated in regions other than their CpG
islands. This conclusion is similar to that drawn from
other studies which found that both the bodies and pro-
moters of highly expressed genes are differentially methyl-
ated compared with inactive genes [30,31,38,50].
Together, our observations point to strikingly different
patterns of methylation at HpaII sites outside of CpG
islands in various tissues. Methylation differences in the
non-CpG-island compartment of the genome are largely
unappreciated and merit further study to understand their
possible functional consequence(s). Of all the tissues ana-
lyzed, cerebellum showed the greatest fluctuations in rel-
ative fragment yield along the chromosome, perhaps
reflecting gross variation in the density of brain-expressed
genes across the chromosome. In contrast, the profiles for
liver, heart and lung showed much less regional variation
with respect to spleen, suggesting a more even distribu-
tion (or lack) of genes expressed specifically in these tis-
sues and associated tissue-specific epigenetic
modifications.
Our findings are consistent with recent studies that have
found a comparatively low frequency of tissue-specific dif-
ferentially methylated regions associated with CpG-island
promoters [33], while differences have been detected in
CpG-poor promoters [26], outside CpG-dense promoters
[36], and in CpG islands far from any known transcrip-
tion start site [64]. Our data also reinforce the conclusions
of Khulan et al. [32], who used a different approach
(HELP) on mouse tissue samples to find that tissue-spe-
cific differentially methylated regions are frequent and not
confined to gene promoter regions. Applying yet another
methylation profiling method (RLGS), two groups found
a highly significant enrichment of differentially methyl-
ated NotI sites away from CpG islands in mouse tissues
[48,65]. Interestingly, a study by Oakes et al. found 8-fold
more hypomethylated NotI sites (among 2,600 analyzed)
in testis than somatic tissues, and found relatively few
brain-specific differentially methylated sites [65]. In con-
trast, we detect many more apparently differentially meth-
ylated regions in cerebellum and other brain parts than
testes when both are compared with spleen.
These observations raise the possibility that hypomethyl-
ation of CpGs outside of CpG islands might correlate with
tissue-specific transcriptional activity of genes or the great
many non-canonical transcripts increasingly being recog-
nized [66]. Indeed, when we compare our measures of rel-
ative methylation of genomic clones on the chromosome
1 array and relative expression levels of constituent genes
measured for the same tissue types in other individuals by
Ge et al. [58], we find that the subsets of array clones with
log2 values above or below our MAD-defined thresholds
(implying relatively low or high methylation, respec-
tively) tend to include genes with higher or lower relative
expression levels, respectively. It is worth noting that the
direction of this trend is similar to that found for promot-
ers, not gene bodies, according to recent large-scale stud-
ies that found gene bodies to be more highly methylated
in highly expressed genes than in inactive genes
[31,38,50]. The regional methylation differences we
observe here might correlate with the density of other
marks of active/inactive chromatin as proposed by Eck-
hardt et al. [33] and/or reflect (or influence) regional com-
partmentalization within the nucleus [67]. Alternatively,
methylation of dispersed CpGs might serve to suppress
spurious transcription from cryptic promoters (as pro-
posed for Arabidopsis [54,68]), raising the interesting
question as to why the relative level of protection by
methylation might vary among tissues.
In conclusion, the methylation landscapes that we have
generated for various tissues suggest a complex pattern of,
and possible function for, methylation differences outside
of CpG islands. Future studies of regional methylation,
regional transcriptional activity, and large-scale organiza-
tion of the nucleus will help further our understanding of
these regional epigenetic differences.
Materials and methods
Tissue samples
Two sets of nine tissues derived from two phenotypically
normal adult individuals, one female and one male, were
provided by the NCI-funded Cooperative Human Tissue
Network http://chtn.nci.nih.gov[69] (CHTN-32364 and
CHTN-32505, respectively).
Digestion, size-fractionation, and labeling of DNA samples
We used spleen as the reference in all tissue comparisons
to keep the denominator for each clone's ratio roughly
constant across our experiments. Spleen DNA was used as
reference for the intra-individual tissue comparisons
because it was the tissue for which DNA was most abun-
dant for both donors. Phenol- and chloroform-extracted
and then isopropanol-precipitated DNA derived from test
and reference tissue samples were divided into tubes (20
to 60 μg per tube) and independently processed and ana-
lyzed. Each DNA sample was digested to completion withEpigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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the methylation-sensitive restriction enzyme, HpaII (New
England Biolabs). We monitored completion of digestion
by agarose gel electrophoresis (data not shown). The
digested DNA was fractionated by size on 5% to 30%
sucrose gradients by using a Beckman SW-40TI swing-out
rotor as previously described [53]. Fractions containing
fragments smaller than 2.5 kb and greater than 80 bp as
judged by gel electrophoresis were selected, pooled, and
precipitated with isopropanol (Figure 1). The resulting
DNA was analyzed by agarose gel electrophoresis to con-
firm that this process had effectively selected fragments 80
to 2,500 bp in length (data not shown). One microgram
each of digested, size-selected test and reference DNA was
differentially labeled with Cy3-dCTP (green) or Cy5-dCTP
(red) (both GE Healthcare), respectively, by random
priming using the Bioprime DNA Labeling System (Invit-
rogen).
Chromosome 1 tiling array hybridization
Preparation and validation of the human chromosome 1
genomic-clone microarray was previously described
[55,70]. Briefly, a total of 2,136 large-insert genomic
clones were spotted in duplicate onto a glass slide. For
simplicity, we will refer to this array as a 'BAC array',
although the spotted clones include BACs, PACs, fosmids,
and cosmids. Of these clones, 2,049 represent a tiling path
covering 213 Mb, approximately 96% of the euchromatic
regions of chromosome 1. Seventeen clones represent
sparsely spaced segments of the X chromosome, with the
first at 35 Mb and the last at 145 Mb with median spacing
of approximately 6 Mb. These clones had been included
on the array as controls for sex-mismatched conventional
array CGH assays for other studies. The remaining 70
clones were included on the array as they were previously
thought to map to chromosomes 1 or X, but are excluded
from the results we report as their chromosomal mapping
is now uncertain. Clone coordinates in the May 2004
assembly of the human genome sequence (Build 35) were
provided by the Sanger Center and are available upon
request. These coordinates typically imply clones longer
than the spans shown on the NCBI or UCSC genome
browsers due to trimming of sequences during genome
assembly to eliminate overlapping sequence.
Labeled test and reference samples were mixed with 85 μg
of Cot-1 DNA (Invitrogen) and hybridized to arrays under
conditions described elsewhere [55]. Each experiment was
done in triplicate using aliquots of the DNA isolated from
each tissue sample, but processed independently. The rep-
licates were independently digested, size selected, labeled
and hybridized, and paired with similarly processed
spleen DNA from the same donor. Replicate arrays of a
given tissue usually employed different independently
processed replicates of the spleen reference DNA as well
(see Additional file 1).
Array data analysis
Image acquisition was performed using an Axon 4000 B
scanner and hybridization intensities were analyzed with
the GenePixPro image analysis software (both Axon
Instruments). For each spot, GenePixPro gave raw inten-
sity values with the surrounding background subtracted
for each wavelength scanned (635 nm and 532 nm for red
and green channels, respectively). A custom R script, Nor-
malization.r, was used to log2-transform these values, cal-
culate the ratio of red to green fluorescence intensities,
and apply a loess normalization procedure [71] based on
GC content of the BACs (see below). A script then proc-
essed the output file to identify and eliminate clones
whose duplicate spots reported significantly different nor-
malized log2 ratios (that is, with standard deviation (SD)
> 0.28) or had been flagged by GenePixPro as bad spots
(that is, spots having less than 80% of pixels with intensi-
ties more than one SD above the background pixel inten-
sity in either wavelength channel). We also eliminated
results for subtelomeric clone RP5-857K21, as it appeared
as an outlier on almost every array. The log2 ratios for the
two spots for each remaining clone were averaged, and the
median of all the clone averages was calculated and set to
zero.
Our computer simulations of the method (see below and
Results) indicated that relative fragment yield at a speci-
fied methylation level, as well as predicted intensity ratios
for a pair of samples having different set methylation lev-
els, vary with the GC content of the clones on the array.
Therefore, we adjusted for GC content as follows: for each
block of spots on each array, a loess curve was fitted to the
relationship between the BACs' GC contents (in per cent)
and their raw log2 ratios. The loess predicted value for
each BAC's log2 ratio based on its GC content was sub-
tracted from its real raw log ratio to give a normalized log
ratio.
Using the GC-normalized data for each array, we then cal-
culated the MAD for a contiguous set of 97 clones in
1q31–1q32 that contains relatively few HpaII sites and
showed little clone-to-clone variation in self-to-self com-
parisons and little deviation from the median in any of
the sample comparisons. This group of clones was used in
each array experiment as an internal measure of experi-
mental noise to help distinguish potentially biologically
meaningful deviations from experimental noise, which
could vary from one array to another. This region of
clones, whose midpoints are between positions
184,314,284 and 196,448,439 bp in chromosome 1's
sequence in Build 35, is marked in each methylation pro-
file with a bar marked 'MAD'. We used the MAD value as
it is relatively robust to outliers and does not assume that
values are normally distributed. The MAD value was cal-
culated by subtracting the median log2 ratio for theseEpigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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selected clones from each clone's log2 ratio to give a devi-
ation value; the MAD value is the median of the absolute
values of these deviations. The SD of a normal distribu-
tion can be estimated to be 1.48 times the MAD value. We
identified clones anywhere on chromosome 1 whose
average log2 ratio values deviated below or above the over-
all median by >4.88 MAD units (that is, >3.29 times the
SD), which would correspond to deviations with statisti-
cal significance at the predictive value of 0.001 based on a
normal distribution with two-sided P value. In the self-to-
self comparisons, we also used all clones to calculate the
MAD and identify outliers beyond the P < 0.001 cutoff.
These outlying values, marked in each methylation profile,
should include loci having true methylation differences
between samples, since only 0.1% of the ratios drawn from
a normal distribution (that is, two false-positive clones per
array) are expected to deviate from the median by >4.88
MAD units. However, this threshold does not exclude all
false positives due to experimental variation. The 97-clone
region of 1q31–32 shows less experimental variation than
the rest of the chromosome even in direct comparisons of
the same tissue sample (for example, female medulla in
Additional file 11). Only 0.5% of the ratios in this direct
comparison deviate from the median by >4.88 MAD units
when MAD is calculated over the entire array, whereas 2.2%
do when MAD is calculated over the 97-clone region.
To control for potential genomic copy number differences
between test and reference genomes, we also competi-
tively hybridized 1 μg each of sonicated test and reference
total DNA, mixed with 100 μg of Cot1 DNA (Invitrogen),
to replicas of the same microarrays using the same condi-
tions as described above [55]. No significant deviations in
copy number were observed across chromosome 1 in any
tissue sample relative to the spleen sample from the same
donor in these conventional array-based comparative
genomic hybridization (array CGH) assays, except the
female lung sample (data not shown). Because log2 ratios
for the methylation-profiling array correlated very
strongly with the wildly varying log2 ratios from the con-
ventional CGH array for this sample (in isolation, each
profile appeared to have large random noise), we elimi-
nated this sample from further analysis. Genomic content
abnormalities were noted for this lung sample in another
study [72].
Note that it is not possible using this comparative method
alone to determine what ratio represents an equivalent
methylation state in test and reference DNA, as is possible
with some sequencing-based methods (for example,
[36,49]). Thus, while a normalized log2 ratio of 0 (the
median) might represent equivalent actual levels of meth-
ylation in a comparison of two normal tissue samples, it
probably would not in a comparison of cells deficient in
DNA methyltransferase activity and control cells.
Methylation simulation
In order to understand the response of our array to differ-
ently methylated genomes, we developed a PERL script,
METHBATCHSIM, to simulate methylation states for a
sequence of interest, such as a particular clone on the
array, and the corresponding yield of fragments through
our methylation-profiling procedure. First, we generated a
list of HpaII restriction sites on the sequence and used
RepeatMasker [56] to generate a repeat-masked sequence
file. METHBATCHSIM reads in the HpaII and masked-
sequence files and randomly designates which restriction
sites in each clone contain methylated CpGs and which
are unmethylated, for a specified overall methylation pro-
portion. Specifically, we used the rbinom function of the
R package [73] to randomly assign methylation status of
each site, using the desired overall methylation fraction
(between 0% and 100%, in steps of 1%) as the 'prob'
parameter, the number of restriction sites in the BAC as
the 'n' parameter, and the 'size' parameter set at 1. The
sequence is then virtually digested with HpaII based on
the assigned methylation states, and we determine which
of the resulting fragments are within the specified size
range (80 to 2,500 bp). We simulated labeling by random
priming by summing the total unmasked base pairs in all
fragments meeting the size-range criterion. The final out-
put summarizes these totals, averaged over 1,000 simula-
tion runs. We repeated this simulation using the sequence
of each clone on the array.
Other bioinformatic analyses
CpG island coordinates were taken from the UCSC
Genome Browser http://genome.ucsc.edu[74] CpG Island
track, where CpG islands are defined as regions of >200
bp with GC content ≥ 50% and a ratio >0.6 of observed
number of CG dinucleotides to expected number on the
basis of the numbers of Gs and Cs in the segment. Gene
coordinates were obtained from the UCSC's RefSeq track.
Expression analysis
In order to test whether the relative methylation levels we
measured relate to transcription levels, we compared our
results with expression data obtained by Ge et al. [58],
who hybridized RNA from each of 36 normal human tis-
sues singly to Affymetrix oligonucleotide microarrays to
determine expression levels of approximately 20,000
human genes. No RNA was available to study expression
levels in samples from the same donors used for our
methylation studies, but because methylation array ratios
were highly correlated between the two donors we stud-
ied, it seemed reasonable to assume that methylation
states would be similar in the tissues of donors used by Ge
et al. and, therefore, reasonable to think that if any con-
sistent correlation between regional methylation and
expression levels exists, it might be observed even if differ-
ent tissue donors are used for the methylation and expres-
sion arrays. We averaged methylation array ratios for theEpigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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same tissue comparisons (that is, across sets of six arrays
for each of cerebellum, heart and liver, and across sets of
three arrays for each of lung, testis and ovary, compared
with spleen in all cases). We used these cross-array aver-
ages to recalculate the MAD-based thresholds used to clas-
sify BACs as having outlying methylation array values.
Starting with Ge et al.'s raw probe-level expression-array
data (GEO series GSE2361), we applied standard back-
ground adjustment, normalization and log-transforma-
tion methods using the robust multi-array average
algorithm from Bioconductor's affy package [75] to
obtain expression levels for each probe set (a probe set is
a set of around 20 oligonucleotide probes that together
represent a portion of a single gene). For each of the six tis-
sue comparisons made (Figure 7, Additional file 10), we
combined normalized expression results for the relevant
tissue types to obtain log2 expression ratios. A table of
Affymetrix probe set names, their corresponding gene
symbols, and genomic coordinates of those genes in Build
35 of the human genome assembly was obtained from the
SCGAP Hematopoietic Stem Cells Project [76]. We then
plotted the expression ratios of probe sets corresponding
to genes whose 5' ends mapped in BACs of each three
implied categories of implied relative methylation levels:
'High', 'Mid' or 'Low'. These conservative classifications
correspond to BACs with ratios on the methylation-sensi-
tive arrays that exceed MAD-based thresholds discussed
above (that is, for Figure 7, 4.88 MAD units from the
median, a threshold chosen such that we would expect
approximately 0.05% of BACs on the array to fall in each
of the Low or High categories by chance). In each boxplot,
the median is indicated by the thick line, the box spans
the middle two quartiles of the distribution, the small cir-
cles are outliers, and the whiskers extend to the most
extreme data point which is no more than 1.5 times the
length of the box away from the box.
In order to test the statistical significance of the observed
differences in relative expression ratios between genes in
BACs of different methylation ratio categories, we needed
to account for the many-to-many relationships that exist
between BACs, genes and probe sets. A BAC can contain
more than one gene, a gene's 5' end can be present in
more than one overlapping BAC, and some genes are rep-
resented on the expression array by more than one probe
set (located in different parts of the gene). We therefore
fitted generalized estimating equations to the data (using
R's geeglm function from the geepack package [77]), treat-
ing datapoints from the same BAC as groups. We also gave
each BAC-probe set datapoint a weight equal to the recip-
rocal of the number of times its gene symbol appeared in
the table of all BAC-probe set pairs (that is, a gene repre-
sented by three probe sets and whose 5' end is in two over-
lapping BACs would receive a weight of 1/6 for each of its
six datapoints). For each tissue comparison, we performed
two statistical tests: (a) a test of whether expression ratios
differ between BACs in the 'High' and 'Low' methylation
categories (P values on square brackets, Figure 7 and Addi-
tional file 10); (b) a trend test for whether expression
ratios are linearly related to methylation category, when
methylation levels are coded as -1 (for low array ratio and
'High' implied relative methylation level), 0 ('Mid'), or 1
(for high array ratio and 'Low' implied relative methyla-
tion level) (P values on arrows, Figure 7 and Additional
file 10). In each test, we used the 'Gaussian' family to
model variation in expression ratios and 'independence'
as the correlation structure.
PCR, cloning and sequencing of bisulfite-modified DNA
Total genomic DNA was extracted from male heart and spleen
samples, and unmethylated cytosines were converted to uracil
by bisulfite treatment according to published protocols [78].
Briefly, each DNA sample was first digested with BamH1, the
enzyme was removed by phenol and chloroform extraction,
and the DNA was subsequently ethanol precipitated and
resuspended in H2O. NaOH was added to each DNA sample
to a final concentration of 0.3 M, and the DNA was denatured
for 2 min at 97°C followed by incubation for 30 min at 39°C.
A solution of sodium bisulfite and hydroquinone was imme-
diately added to 3.3 M and 0.67 mM final concentrations,
respectively, and samples were incubated for 16 h at 55°C
with 95°C spikes for 5 min every 3 h. Samples were desalted
using QIAquick PCR Purification columns (Qiagen) accord-
ing to the manufacturer's instructions. NaOH was added to
each converted sample to a final concentration of 0.3 M, and
the samples were incubated at 37°C for 15 min to remove
excess sodium bisulfite. DNA samples were then ethanol pre-
cipitated and resuspended in 100 μl H2O.
Primers for selected regions were designed using the
BiSearch Web Server [79] and are provided upon request.
Each amplification was done with touchdown PCR using
2 μl Ex-Taq enzyme (Takara Mirus Bio) and 0.5 μl of 50
μM primers in a total volume of 25 μl with the following
conditions: 95°C for 2 min, 30 cycles of 95°C for 30s,
66°C for 30s (stepping down 2°C every 2 cycles until
56°C), and 72°C for 1 min, followed by 72°C for 10 min.
Amplified products from converted DNA were gel-puri-
fied with QIAquick Gel Extraction columns (Qiagen)
according to the manufacturer's instructions and subse-
quently cloned into the pCR2.1 plasmid vector using the
TOPO TA Cloning Kit (Invitrogen). Clones with inserts
were identified by PCR amplification using M13 reverse
and T7 forward primers using TOPO cloning instructions.
Amplified M13-T7 products were purified with Sephacryl
S-300 (Amersham BioSciences). Seven to thirty-two
clones were then sequenced successfully from each PCR
product using the same primers on an ABI 3730 (Applied
Biosystems). Sequences were aligned and analyzed using
PhredPhrap and Consed [80-82].Epigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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All array data relevant to this manuscript have been sub-
mitted to the Gene Expression Omnibus (GEO) under
accession number GSE12925.
Abbreviations
ATP2B4: Ca-transporting plasma membrane ATPase iso-
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ryanodine cardiac receptor 2; SD: standard deviation.
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Additional material
Additional File 1
Table S1. Replicates of test and spleen reference paired for each array.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S1.xls]
Additional File 2
Figure S1. Scatter plots are displayed above the diagonal to illustrate pair-
wise comparisons between results of different methylation profiling micro-
array experiments. The corresponding Pearson R2 correlation coefficients 
are shown below the diagonal. This figure includes three replicate arrays 
each for various tissue samples from each of two donors. Female lung is 
excluded due to observed genomic copy number deviations. Only cerebel-
lum is included in this set as a representative brain part due to space con-
siderations. The reference tissue in each array is spleen, from the same 
donor as the test tissue. The red dashed line in each plot indicates the lin-
ear regression fit. Cells along the diagonal provide tissue and replicate 
information. Abbreviation: Cere, Cerebellum. Replicates are indicated by 
the suffix following the underscore: M1, M2, and M3 are replicates from 
the male donor; F1, F2, F3 are replicates from the female donor. Most rep-
licate arrays for a given tissue employed different replicates of the spleen 
reference (see Additional file 1).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S2.jpeg]
Additional File 3
Figure S2. Scatter plots are displayed above the diagonal to illustrate pairwise 
comparisons between results of different methylation profiling microarray 
experiments performed using various brain tissue samples. The corresponding 
Pearson R2 correlation coefficients are shown below the diagonal. This figure 
includes three replicate arrays for each tissue sample from each of two donors. 
Abbreviations: Cere, Cerebellum; Occi, Occipital Lobe; Med, Medulla. See 
Additional file 2 legend for additional details. Plots comparing F1 brain sam-
ples are also shown in Figures 5B, 5C, and 5D.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S3.jpeg]
Additional File 4
Figure S3. Scatter plots are displayed above the diagonal to illustrate pair-
wise comparisons between results of different methylation profiling micro-
array experiments performed using various tissues from two donors. Here 
one representative replicate of each tissue from each donor is included in 
the pairwise comparison dataset. The corresponding Pearson R2 correla-
tion coefficients are shown below the diagonal. See Additional file 2 leg-
end for additional details.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S4.jpeg]
Additional File 5
Figure S4. Hierarchical clustering of methylation profiles from 45 frac-
tionated DNA samples from 15 tissue samples. GC-normalized ratios 
were clustered using Manhattan distances and the Ward method of hier-
archical clustering using R's hclust function. The dendrogram demon-
strates that there is tight correlation within each set of triplicate samples 
and between samples from the same tissue in different individuals. Abbre-
viations: Med, Medulla; Cere, Cerebellum; Occi, Occipital Lobe.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S5.pdf]
Additional File 6
Figure S5. Chromosome 1 G-banding, GC%, gene density, and HpaII 
site distribution. The G-banding pattern of chromosome 1 is aligned to 
plots of (1) of the percentage of G or C nucleotides in each array clone as 
a function of the clone's position along the chromosome, (2) of the 
number of start sites of RefSeq genes in non-overlapping windows of 1 
Mbp along the chromosome (obtained from the UCSC Genome Browser 
RefSeq track), and (3) the number of possible HpaII fragments in the 80 
to 2,500 bp size range in each array clone as a function of the clone's posi-
tion along the chromosome. The thick black bar indicates the region of 97 
clones used to calculate median absolute deviation values in all experi-
ments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S6.pdf]Epigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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Additional File 7
Figure S6. Reproducibility of methylation profiles across three experiments in 
which heart DNA is compared with spleen using tissue from the male donor. 
DNA was extracted from a single heart and single spleen tissue sample, and 
each DNA preparation was then divided into aliquots that were independently 
processed through HpaII digestion, size selection, labeling, and array hybridiza-
tion. Replicates are identified as M1, M2, and M3 for heart, and M1, M6, and 
M7 for spleen, where M denotes the male donor. (A) Profiles of log2 ratios as 
function of genomic position. Clones highlighted in black, red, or blue have log2 
ratios that deviate from the median by >4.88 median absolute deviation, which 
was calculated over the region indicated with a wide bar. The clone whose value 
is indicated in red is RP11-47A4, which contains part of the RYR2 gene; the 
value in blue is for clone RP11-90O23, which contains ATP2B4. Sequences 
encompassed by these clones are the subject of our bisulfite sequencing analyses. 
(B) Correlations of log2 ratios measured in the three pairs of experiments. Scat-
terplots are shown above the diagonal; values below the diagonal are the corre-
sponding Pearson correlation coefficients (R2).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S7.pdf]
Additional File 8
Figure S7. Enlarged view of clones on the array around the region containing 
the ryanodine cardiac receptor 2 gene (RYR2). Relative positions of bacterial 
artificial chromosomes (BACs) covering the region flanking RP11-47A4 
(AL391809) and their corresponding mean log2 ratios (dotted lines are at ± 
1 standard error of the mean) in six heart-versus-spleen methylation profiles 
(three using DNA prepared from tissue from the female donor, and three uti-
lizing DNA from tissue from the male donor). RP11-47A4 has the highest 
mean log2 ratio value of the five BACs shown here. The relative positions of 
RYR2 exons are indicated by black dots (size not to scale) and the RYR2 CpG 
island, which coincides with RYR2's first exon is indicated. RYR2 extends 
approximately 340 kb beyond the region shown.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S8.pdf]
Additional File 9
Figure S8. Methylation status of CpGs in RP11-47A4 (AL391809), which 
contains the RYR2 gene, as determined by sequencing of PCR products ampli-
fied after bisulfite conversion of unmethylated cytosines to uracil. These data are 
summarized in Figure 6. Here, the raw data are provided for each sequenced 
amplicon from heart or spleen. Filled squares represent methylated CpG dinu-
cleotides, open squares unmethylated CpGs, and gray background shading 
denotes CpGs that are part of HpaII restriction sites.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S9.pdf]
Additional File 10
Figure S9. Expression ratios tend to be higher for genes whose 5' ends fall 
in regions of lower methylation (that is, in bacterial artificial chromo-
somes (BACs) with higher methylation array ratios) than those in regions 
of higher methylation. Data are presented as in Figure 7, but here BACs 
are classified in the 'High' and 'Low' categories using a less conservative 
methylation array ratio threshold. This less conservative threshold is 
defined as 2.91 * median absolute deviation (MAD) units below and 
above the median value. At the 2.91 * MAD threshold, we expect approx-
imately 2.5% of BACs on the array to fall into each of the 'High' and 
'Low' categories purely by chance (that is, an overall false-positive rate of 
5% of array BACs). Figure 7 conservatively uses 4.88 * MAD, such that 
the false-positive rate is expected to be only around 0.1% of the BACs on 
the array. The increased number of BACs in the 'High' and 'Low' catego-
ries using this less conservative approach likely gives the statistical tests 
greater power, explaining the greater significance of most P values shown 
here as compared with Figure 7.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S10.pdf]
Additional File 11
Figure S10. Methylation profile in which two independently processed 
aliquots of DNA isolated from medulla tissue from the same female donor 
are directly compared. The log2 ratios for chromosome 1 clones are indi-
cated at their relative genomic position, with the large gap representing the 
centromere and pericentromeric repeats in 1p11–1q21. The horizontal 
scale for the X chromosome is compressed; the 17 chromosome X clones on 
the array are distributed over 110 Mb. Clones highlighted in black or red 
have log2 ratios that deviate from the overall median, set here to 0, in 
either direction by >4.88 median absolute deviation (MAD) units, where 
MAD units are calculated using the data for the clones in the region of 1q 
marked 'MAD', which showed the least biological variation within and 
across experiments. Clones highlighted in red deviate from the overall 
median by ± 4.88 MAD, calculated using all values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
8935-2-7-S11.pdf]Epigenetics & Chromatin 2009, 2:7 http://www.epigeneticsandchromatin.com/content/2/1/7
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